LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain
Keywords:pain, psychedelics, psilocybin, nociplastic, LSD
Healthcare providers face the challenging task of managing patients who suffer from chronic nociplastic pain conditions. Pain is a multidimensional experience, and the current approach to managing people in chronic pain often fails to meet the needs of these patients. Novel ways of treating people who suffer from chronic nociplastic pain with classic psychedelic agents may offer a new lens through which to approach their pain. Lysergic acid diethylamide (LSD) and psilocybin are both serotonergic agents with a long history of use in treating people with chronic pain and mental health disorders. The new wave of research into psychedelics for major depressive disorder provides an opportunity to investigate and understand the potential for incorporating these drugs into chronic pain management pathways. This narrative review presents healthcare workers with a framework to understand the method of action of these drugs in chronic nociplastic pain pathways and a brief history into their use. We conducted an online search using Pubmed with keywords ‘chronic pain’ AND/OR ‘psilocybin’ AND/OR ‘lysergic acid diethylamide’ AND/OR ‘psychedelics’ with no date limit applied. We identified further articles that contained information on the neuroscience of psychedelics and the serotonergic system using Google Scholar. During the final stages of writing the article, the latest publications on psychedelics and chronic pain in leading pain journals were again included to update the information.
Isa A, Chetty S. Physiology and pathophysiology of chronic pain (Part I). S Afr J Anaesth Analg 2021;27(6):266-270. https://doi.org/10.36303/sajaa.2021.27.6.2491
Stilwell P, Hudon A, Meldrum K, Pagé MG, Wideman TH. What is pain-related suffering? Conceptual critiques, key attributes, and outstanding questions. J Pain 2022;23(5):729-738. https://doi.org/10.1016/j. jpain.2021.11.005
Das S, Maiti T. Lysergic acid diethylamide as an analgesic agent in patients with terminal illnesses. J Pain Manag 2020;10(1):9-12. https://doi.org/10.2217/pmt-2019-0043
Fitzcharles M-A, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociplastic pain: Towards an understanding of prevalent pain conditions. Lancet 2021;397(10289):2098-2110. https://doi. org/10.1016/s0140-6736(21)00392-5
Melzack R. From the gate to the neuromatrix. J Pain 1999;82(Supplement 1):S121-S126. https://doi. org/10.1016/s0304-3959(99)00145-1
Sheng J, Liu S, Wang Y, Cui R, Zhang X. The link between depression and chronic pain: Neural mechanisms in the brain. Neural Plast 2017;2017:1-10. https://doi.org/10.1155/2017/9724371
IsHak WW, Wen RY, Naghdechi L, et al. Pain and depression: A systematic review. Harv Rev Psychiatry 2018;26(6):352-363. https://doi.org/10.1097/hrp.0000000000000198
Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 2014;202(7):513- 520. https://doi.org/10.1097/nmd.0000000000000113
Kurland AA. LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs 1985;17(4):279-290. https://doi.org/10.1080/02791072.1985.10524332
Cohen SP, Vase L, Hooten WM. Chronic pain: An update on burden, best practices, and new advances. Lancet 2021;397(10289):2082-2097. https://doi.org/10.1016/s0140-6736(21)00393-7
WhelanA,JohnsonMI.Lysergicaciddiethylamideandpsilocybinforthemanagementofpatientswith persistent pain: A potential role? J Pain Manag 2018;8(3):217-229. https://doi.org/10.2217/pmt-2017- 0068
Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 2017;42(11):2105-2113. https://doi.org/10.1038/npp.2017.84
Tao Z-Y, Wang P-X, Wei S-Q, Traub RJ, Li J-F, Cao D-Y. The role of descending pain modulation in chronic primary pain: Potential application of drugs targeting serotonergic system. Neural Plast 2019;2019:1-16. https://doi.org/10.1155/2019/1389296
Čeko M, Frangos E, Gracely J, et al. Default mode network changes in fibromyalgia patients are largely dependent on current clinical pain. NeuroImage 2020;216:116877. https://doi.org/10.1016/j. neuroimage.2020.116877
Johnson MW, Andrew Sewell R, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend 2012;123(1-3):132-140. https://doi. org/10.1016/j.drugalcdep.2011.10.029
Meade E, Hehir S, Rowan N, Garvey M. Mycotherapy: Potential of fungal bioactives for the treatment of mental health disorders and morbidities of chronic pain. J Fungi 2022;8(3):290. https://doi. org/10.3390/jof8030290
Carhart-Harris RL, Leech R, Hellyer PJ, et al. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 2014;8. https://doi. org/10.3389/fnhum.2014.00020
Liechti ME. Modern clinical research on LSD. Neuropsychopharmacology 2017;42(11):2114-2127.
Weil AT. Drug, set, and setting: The basis for controlled intoxicant use. J Psychoactive Drugs 1984;16(3):271. https://doi.org/10.1080/02791072.1984.10524320
Kast EC, Collins VJ. Study of lysergic acid diethylamide as an analgesic agent. Anesth Analg 1964;43(3):285-291. https://doi.org/10.1213/00000539-196405000-00013
Kast E. Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatr Q 1967;41(4):646-657. https://doi.org/10.1007/bf01575629
Pahnke WN, Kurland AA, Goodman LE, Richards WA. LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther 1969;9:144-152.
Grof S, Goodman LE, Richards WA, Kurland AA. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 1973;8(3):129-144. https://doi.org/10.1159/000467984
Fanciullacci M, Bene ED, Franchi G, Sicuteri F. Phantom limb pain: Sub-hallucinogenic treatment
with lysergic acid diethylamide (LSD-25). J Headache Pain 1977;17(3):118-119. https://doi.
Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. J Neurol 2006;66(12):1920-1922. https://doi.org/10.1212/01.wnl.0000219761.05466.43
Schindler EAD, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine hallucinogens in cluster headache: Results of the clusterbusters medication use survey. J Psychoactive Drugs 2015;47(5):372-381. https://doi.org/10.1080/02791072.2015.1107664
Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomised double- blind trial. J Psychopharmacology 2016;30(12):1181-1197. https://doi.org/10.1177/0269881116675513
Bornemann J, Close JB, Spriggs MJ, Carhart-Harris R, Roseman L. Self-medication for chronic pain using classic psychedelics: A qualitative investigation to inform future research. Front Psychiatry 2021;12. https://doi.org/10.3389/fpsyt.2021.735427
Lyes M, Yang KH, Castellanos J, Furnish T. Microdosing psilocybin for chronic pain: A case series. J Pain 2022;164(4):698-702. https://doi.org/10.1097/j.pain.0000000000002778
Isa A, Chetty S. Physiology and pathophysiology of chronic pain (Part II): how does pain become chronic? South Afr J Anaesth Analg 2022;28(1):11-14. https://doi.org/10.36303/sajaa.2022.28.1.2497
Wei S-Q, Tao Z-Y, Xue Y, Cao D-Y. Peripheral sensitisation. In: Turker H, Garcia Benavides L, Ramos Gallardo G, Méndez Del Villar M (eds). Peripheral Nerve Disorders and Treatment. London: IntechOpen, 2022. https://doi.org/10.5772/intechopen.90319
Di Lernia D, Serino S, Riva G. Pain in the body. Altered interoception in chronic pain conditions: A systematic review. Neurosci Biobehav Rev 2016;71:328-341. https://doi.org/10.1016/j. neubiorev.2016.09.015
Uddin LQ, Nomi JS, Hébert-Seropian B, Ghaziri J, Boucher O. Structure and function of the human insula. J Clin Neurophysiol 2017;34(4):300-306. https://doi.org/10.1097/wnp.0000000000000377
Doan L, Manders T, Wang J. Neuroplasticity underlying the comorbidity of pain and depression.
Neural Plast 2015;2015:1-16. https://doi.org/10.1155/2015/504691
Das S, Barnwal P, Ramasamy A, Sen S, Mondal S. Lysergic acid diethylamide: A drug of ‘use’? Ther Adv
Psychopharmacol 2016;6(3):214-228. https://doi.org/10.1177/2045125316640440
Haleem DJ. Targeting serotonin1a receptors for treating chronic pain and depression. Curr
Neuropharmacol 2019;17(12):1098-1108. https://doi.org/10.2174/1570159x17666190811161807
Ji R-R, Berta T, Nedergaard M. Glia and pain: Is chronic pain a gliopathy? J Pain 2013;154(suppl
Edinoff AN, Fort JM, Singh C, et al. Alternative options for complex, recurrent pain states using
cannabinoids, psilocybin, and ketamine: A narrative review of clinical evidence. Neurol Int
Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity.
Cell Rep 2018;23(11):3170-3182. https://doi.org/10.1016/j.celrep.2018.05.022
Callard F, Margulies DS. What we talk about when we talk about the default mode network. Front Hum
Neurosci 2014;8:619. https://doi.org/10.3389/fnhum.2014.00619
Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default network: Anatomy, function, and
relevance to disease. Ann N Y Acad Sci 2008;1124:1-38. https://doi.org/10.1196/annals.1440.011
Tozzi L, Zhang X, Chesnut M, Holt-Gosselin B, Ramirez CA, Williams LM. Reduced functional connectivity of default mode network subsystems in depression: Meta-analytic evidence and relationship with trait rumination. NeuroImage: Clinical 2021;30:102570. https://doi.org/10.1016/j.
Hashmi JA, Baliki MN, Huang L, et al. Shape shifting pain: Chronification of back pain shifts brain representation from nociceptive to emotional circuits. J Brain 2013;136(9):2751-2768. https://doi. org/10.1093/brain/awt211
Loggia ML, Kim J, Gollub RL, et al. Default mode network connectivity encodes clinical pain: An arterial spin labeling study. J Pain 2013;154(1):24-33. https://doi.org/10.1016/j.pain.2012.07.029
Carhart-Harris RL. The entropic brain – revisited. J Neuropharmacol 2018;142:167-178. https://doi. org/10.1016/j.neuropharm.2018.03.010
Carhart-Harris R, Nutt D. Serotonin and brain function: A tale of two receptors. J Psychopharmacol 2017;31(9):1091-120. https://doi.org/10.1177/0269881117725915
Baliki MN, Baria AT, Apkarian AV. The cortical rhythms of chronic back pain. J Neurosci 2011;31(39):13981-13990. https://doi.org/10.1523/jneurosci.1984-11.2011
Zhang G, Stackman RW. The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol 2015;6:225. https://doi.org/10.3389/fphar.2015.00225
Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: Descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 2004;25(12):613-617. https://doi.org/10.1016/j. tips.2004.10.002
Szabo A. Psychedelics and immunomodulation: Novel approaches and therapeutic opportunities. Front Immunol 2015;6:358. https://doi.org/10.3389/fimmu.2015.00358
Bardin L. The complex role of serotonin and 5-HT receptors in chronic pain. Behav Pharmacol 2011;22(5 and 6):390-404. https://doi.org/10.1097/fbp.0b013e328349aae4
Copyright (c) 2023 J Van Der Walt, R Parker
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.